For people with stable finances, a volatile market can be a great time to invest.
News & Analysis: Gilead Sciences
The stock is up just 2% in the past three months.
The European Commission has granted conditional approval to Veklury, the antiviral known as remdesivir.
Optimism about Gilead’s COVID-19 treatment boosted the shares.
Is an industry leader in treating cystic fibrosis or a company with a potential miracle drug the better buy for investors?
In the U.S., a health insurer insurer should be billed $3,120 per treatment course.
These companies have products, products, and more products to keep revenue flowing.
A key advisory team has given remdesivir a thumbs up, clearing the way to an official green light for its use in Europe.
Gilead will take a chance on privately held Pionyr Immunotherapeutics and its unique cancer treatment candidates.
Sorrento has more momentum right now. But does Gilead's pipeline and dividend make it the better pick?